Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Basilea Pharmaceutica AG 0QNA.L
$46.23
+$0.13 (0.27%)
На 18:02, 12 мая 2023
Ключевые показатели
-
Marketcap
500001600.00000000
-
week52high
55.30
-
week52low
29.80
-
Revenue
-
P/E TTM
0
-
Beta
0.84160300
-
EPS
-0.58500000
-
Last Dividend
0.00000000
-
Next Earnings Date
07 мая 2023 г. в 04:54
Описание компании
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Свежие комментарии
Свежие комментарии